Direct and indirect costs of systemic sclerosis and associated interstitial lung disease: A nationwide population-based cohort study
- PMID: 35224821
- PMCID: PMC9306585
- DOI: 10.1111/resp.14234
Direct and indirect costs of systemic sclerosis and associated interstitial lung disease: A nationwide population-based cohort study
Abstract
Background and objective: The study aimed to evaluate the direct and indirect costs of systemic sclerosis (SSc) in cases with and without interstitial lung disease (ILD).
Methods: Cases diagnosed with SSc (2002-2015) were identified in the Danish National Patient Registry. Cases were matched 1:4 with non-SSc controls from the general population. Data on costs were obtained from national databases. Excess cost was estimated as the annual cost per case subtracting the costs of the control.
Results: We identified 1869 cases and 7463 controls. Total excess cost (direct healthcare, elderly care and indirect costs) in the SSc-ILD cohort was €29,725, and €17,905 in the non-ILD SSc cohort. In- and out-patient contacts and forgone earnings were the key drivers of costs in both cohorts. Healthcare costs were higher before and after the diagnosis compared with the controls. Men incurred higher excess healthcare costs than women. Hospitalization and outpatient services were the key drivers of the gender-associated differences. Income from employment decreased more rapidly after diagnosis in the SSc-ILD cohort than in the non-ILD SSc cohort. Public transfer income increased after diagnosis, with the most pronounced difference in the SSc-ILD cohort. Disability pension was the key driver of public transfer income.
Conclusion: SSc is associated with a significant individual and societal burden that is evident several years before and after the diagnosis. Total excess costs are higher in SSc-ILD than in the non-ILD SSc underlining the severity of pulmonary involvement. Initiatives to maintain work ability and to reduce hospital admissions may reduce the economic burden of SSc.
Keywords: cost of illness; direct healthcare cost; healthcare cost; indirect costs; systemic sclerosis-associated interstitial lung disease.
© 2022 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology.
Conflict of interest statement
Ole Hilberg has received an unrestricted grant from Boehringer Ingelheim A/S for the current work. Outside the current work, Malene Knarborg has received a fee from AstraZenica A/S. Melina Gade Sikjær, Anders Løkke and Rikke Ibsen declare no competing interests.
Figures


Comment in
-
The hidden costs of living with systemic sclerosis-associated interstitial lung disease.Respirology. 2022 Jul;27(7):486-487. doi: 10.1111/resp.14275. Epub 2022 May 10. Respirology. 2022. PMID: 35538640 No abstract available.
Similar articles
-
Economic Burden of Illness Among Commercially Insured Patients with Systemic Sclerosis with Interstitial Lung Disease in the USA: A Claims Data Analysis.Adv Ther. 2019 May;36(5):1100-1113. doi: 10.1007/s12325-019-00929-2. Epub 2019 Mar 30. Adv Ther. 2019. PMID: 30929184 Free PMC article.
-
The clinical and economic burden of systemic sclerosis related interstitial lung disease.Rheumatology (Oxford). 2020 Aug 1;59(8):1878-1888. doi: 10.1093/rheumatology/kez532. Rheumatology (Oxford). 2020. PMID: 31740961
-
Healthcare Resource Utilization Among Patients in England with Systemic Sclerosis-Associated Interstitial Lung Disease: A Retrospective Database Analysis.Adv Ther. 2020 May;37(5):2460-2476. doi: 10.1007/s12325-020-01330-0. Epub 2020 Apr 21. Adv Ther. 2020. PMID: 32319038 Free PMC article.
-
Healthcare utilization and economic burden in systemic sclerosis: a systematic review.Rheumatology (Oxford). 2022 Aug 3;61(8):3123-3131. doi: 10.1093/rheumatology/keab847. Rheumatology (Oxford). 2022. PMID: 34849627
-
Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).Front Immunol. 2020 Sep 4;11:1990. doi: 10.3389/fimmu.2020.01990. eCollection 2020. Front Immunol. 2020. PMID: 33013852 Free PMC article. Review.
Cited by
-
CONQUER Scleroderma: association of gastrointestinal tract symptoms in early disease with resource utilization.Rheumatology (Oxford). 2023 Oct 3;62(10):3433-3438. doi: 10.1093/rheumatology/kead176. Rheumatology (Oxford). 2023. PMID: 37079727 Free PMC article.
-
Comorbidity and mortality in systemic sclerosis and matched controls: Impact of interstitial lung disease. A population based cohort study based on health registry data.Chron Respir Dis. 2023 Jan-Dec;20:14799731231195041. doi: 10.1177/14799731231195041. Chron Respir Dis. 2023. PMID: 37596992 Free PMC article.
-
Scoping Review of Economic Analyses of Rare Kidney Diseases.Kidney Int Rep. 2024 Sep 12;9(12):3553-3569. doi: 10.1016/j.ekir.2024.09.004. eCollection 2024 Dec. Kidney Int Rep. 2024. PMID: 39698356 Free PMC article.
-
Burden of Disease and Productivity Loss in the European Economic Area in Patients Affected by Fibrosing Interstitial Lung Disease.Adv Ther. 2023 Dec;40(12):5502-5518. doi: 10.1007/s12325-023-02701-z. Epub 2023 Oct 14. Adv Ther. 2023. PMID: 37837527 Free PMC article.
-
Systematic Scoping Review of Socioeconomic Burden and Associated Psychosocial Impact in Patients With Rare Kidney Diseases and Their Caregivers.Kidney Int Rep. 2024 Dec 10;10(3):838-854. doi: 10.1016/j.ekir.2024.12.005. eCollection 2025 Mar. Kidney Int Rep. 2024. PMID: 40225371 Free PMC article.
References
-
- Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685–99. - PubMed
-
- Hudson M, Steele R, Lu Y, Thombs BD, Baron M. Work disability in systemic sclerosis. J Rheumatol. 2009;36(11):2481–6. - PubMed
-
- Tyndall AJ, Bannert B, Vonk M, Airò P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69(10):1809–15. - PubMed
-
- Mayes MD, Lacey JV Jr, Beebe‐Dimmer J, Gillespie BW, Cooper B, Laing TJ, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003;48(8):2246–55. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical